Quick Answer
VYNE Therapeutics Inc. reported Net Income of -$26.48 million for fiscal year 2025.
VYNE Therapeutics Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$26.48M | +33.5% |
| 2024 | -$39.83M | -40.0% |
| 2023 | -$28.45M | -22.6% |
| 2022 | -$23.21M | +68.3% |
| 2021 | -$73.33M | +71.3% |
| 2020 | -$255.57M | -168.5% |
| 2019 | -$95.18M | -28.3% |
| 2018 | -$74.16M | -155.1% |
| 2017 | -$29.08M | -106.7% |
| 2016 | -$14.07M | -205.3% |
| 2015 | -$4.61M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | -$5.75M | +38.8% | +33.2% |
| March 31, 2025 | -$8.61M | -37.8% | +29.2% |
| September 30, 2024 | -$12.16M | -84.6% | -29.2% |
| June 30, 2024 | -$9.41M | +6.5% | -50.5% |
| March 31, 2024 | -$6.25M | -11.2% | +5.1% |
| September 30, 2023 | -$6.58M | +30.4% | +34.5% |
| June 30, 2023 | -$10.06M | -18.7% | -78.9% |
| March 31, 2023 | -$5.62M | -220.4% | +40.6% |
- VYNE Therapeutics Inc. showed an increase of +33.5% in Net Income compared to the prior fiscal year.
- Over the 2015–2025 period, VYNE Therapeutics Inc.’s net income has declined by 474.7% (from -$4.61 million to -$26.48 million).
- The most recent figure is from VYNE Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: